Profibrotic and proinflammatory pathway proteins

Profibrotic and proinflammatory pathway proteins represent a broad and heterogeneous group of molecular entities, including cytokines, growth factors, and enzymes, that collectively orchestrate the body's response to injury and chronic stress [1: Wynn, 2008, J. Pathol.]. Key members of this group, such as Transforming Growth Factor-beta (TGF-beta), Galectin-3, and various Interleukins (e.g., IL-1, IL-6), play dual roles in promoting persistent inflammation and the subsequent activation of myofibroblasts [2: Henderson et al., 2014, JCI; 3: Meng et al., 2016, Nat. Rev. Nephrol.]. This activation leads to excessive extracellular matrix (ECM) deposition and tissue scarring, which are hallmarks of progressive diseases like idiopathic pulmonary fibrosis, cirrhosis, and chronic kidney disease [4: Richeldi et al., 2017, Lancet]. Therapeutic strategies targeting these proteins aim to interrupt these signaling loops to halt or reverse disease progression using small molecules or monoclonal antibodies [5: FDA Label for Ofev]. However, because many of these proteins also have essential roles in normal homeostasis and wound repair, achieving selectivity and avoiding systemic side effects like immunosuppression remains a significant challenge in drug development [6: Rosenbloom et al., 2017, Nat. Rev. Rheumatol.].

Inhibition of signaling cascades (e.g., TGF-beta/Smad, MAPK) and neutralization of soluble mediators (e.g., TNF-alpha, IL-6) to prevent the transition from acute inflammation to chronic tissue remodeling and myofibroblast-driven collagen deposition.